首页> 外文OA文献 >P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

【2h】

P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

机译：P1.01-95 Anlotinib与化疗结合化疗的疗效和安全性作为先进的非小细胞肺癌（NSCLC）患者的一线治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
B. Han; T. Chu; X. Zhang; H. Zhong; B. Zhang; H. Wang; A. Gu; W. Zhang; C. Shi; R. Zhong;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 6594 POSTER First-line bevacizumab in combination with chemotherapy in the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): an open-label safety study (MO19390) [J] . L.Crinó, E.Dansin, P.Garrido Lopez, European Journal of Cancer Supplements . 2007,第4期

机译：6594海报一线贝伐单抗联合化疗治疗晚期或复发性非鳞状非小细胞肺癌（NSCLC）患者：一项开放性安全研究（MO19390）
2. AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla11期

机译：AvaALL：开放标签随机1Mb临床试验，评估在初次手术后晚期非鳞状非小细胞肺癌（NSCLC）患者病情进展之外，是否进行持续贝伐单抗（BV）治疗的标准治疗的有效性和安全性BV加上铂金双线化疗（CT）的线（1L）治疗
3. 9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390) [J] . P.Garrido, N.Thatcher, L.Crino, European Journal of Cancer Supplements . 2009,第2期

机译：9170贝伐单抗（Bv）一线联合化疗对晚期或复发性非鳞状非小细胞肺癌（NSCLC）老年患者（pts）的安全性和有效性：SAiL（MO19390）
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
6. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer [O] . Hai-ying Wang, Jun-feng Chu, Yan Zhao, 2020

机译：一种试验化疗的安全性和疗效加上anlotinib与化疗单独作为前进的非小细胞肺癌的二线或第三线救死治疗
7. P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [O] . B. Han, T. Chu, C. Shi, 2019

机译：P2.01-21梳理蒽虫和厄洛替尼作为先进非小细胞肺癌患者的一线治疗（NSCLC）的疗效和安全性

P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

著录项

引文网络

相似文献

相关主题

期刊订阅